BlueCross BlueShield
Federal Employee Program
Federal Employee Program®
1310 G Street, N.W.
Washington, D.C. 20005
202.942.1000
Fax 202.942.1125

5.40.028

Section:	Prescription Drugs	**Effective Date:**	April 1, 2023
Subsection:	Cardiovascular Agents	**Original Policy Date:**	January 1, 2021
Subject:	Tikosyn	**Page:**	1 of 3

Last Review Date: March 10, 2023

Tikosyn

Description

Tikosyn (dofetilide)

Background
Tikosyn (dofetilide) is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. Tikosyn blocks cardiac ion channels carrying the rapid component of the delayed rectifier potassium current I_{KR}. At clinically relevant concentrations, Tikosyn has no effect on sodium channels, adrenergic alpha-receptors, or adrenergic beta-receptors (1).

Regulatory Status
FDA-approved indication: Tikosyn is indicated in patients with atrial fibrillation/atrial flutter (1).

Related policies

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Tikosyn may be considered **medically necessary** for patients with atrial fibrillation or atrial flutter who have had an inadequate response, intolerance, or contraindication to the generic.

Tikosyn may be considered **investigational** for all other diagnoses.

Prior-Approval Requirements

Diagnosis

Patient must have the following:

Atrial fibrillation / Atrial flutter

a. Patient **MUST** have tried the preferred product (generic Tikosyn: dofetilide) unless the patient has a valid medical exception (e.g., inadequate treatment response, intolerance, contraindication)

Prior – Approval *Renewal* Requirements

Same as above

Policy Guidelines

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Tikosyn (dofetilide) is and antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties. Tikosyn blocks cardiac ion channels carrying the rapid component of the delayed rectifier potassium current I_{KR}. At clinically relevant concentrations, Tikosyn has no effect on sodium channels, adrenergic alpha-receptors, or adrenergic beta-receptors (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Tikosyn while maintaining optimal therapeutic outcomes.

References

1. Tikosyn [package insert]. New York, NY: Pfizer Inc.; July 2021.

Policy History

Date	Action
December 2020	Addition to PA. Annual review
December 2021	Annual review and reference update
December 2022	Annual review. Changed policy number to 5.40.028
March 2023	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 10, 2023 and is effective on April 1, 2023.